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The median dose for patients receiving BM (2.7  108/Kg) gave
the greatest discrimination.
In multivariate analyses, high dose BM compared to PB, was asso-
ciated with lower TRM (RR  0.61 ; 95% CI 0.39-0.98; p  0.04),
better Leukemia Free Survival (RR  0.65; 95% CI 0.46-0.91; p 
0.013), and better Overall Survival (RR  0.64 ; 95% CI 0.44-0.92;
p  0.016). Conclusion: The present study in patients with AML
allografted in ﬁrst remission, indicates a better outcome with marrow
as compared to PB, when the dose of marrow infused is rich.
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LONG-TERM FOLLOW UP AFTER NON-MYELOABLATIVE ALLOGENEIC
STEM CELL TRANSPLANTATION FOR RENAL CELL CARCINOMA: THE
UNIVERSITY OF CHICAGO EXPERIENCE
Artz, A.S.1, van Besien, K.1, Zimmerman, T.1, Gajewski, T.F.1, Rini,
B.2, Hu, S.3, Stadler, W.M.1, Vogelzang, N.J.1 1. University of Chicago
Hospitals, Chicago, IL; 2. The University of California San Francisco,
San Francisco, CA; 3. St. John Mercy Medical Center, St. Louis, MO
Non-myeloablative hematopoietic allogeneic stem cell transplant
(NST) for metastatic renal cell carcinoma (RCC) has been dem-
onstrated to induce remissions in select patients (pts). However,
there are no long-term data on response duration, progression
after response, or overall survival. We report the long-term follow
up of NST for cytokine refractory metastatic RCC at the Univer-
sity of Chicago treated on a single protocol. Between 2/99 and
5/03, 18 pts underwent 19 matched-sibling peripheral harvested
NST’s after conditioning with ﬂudarabine and cyclophosphamide.
Post-transplant immunosuppression was with mycophenolate
mofetil until day 60 and tacrolimus tapering at day 90. Median age
was 55 years, performance status (PS) was 1 in 6/19 pts (PS  0 in
the remainder), and hemoglobin (Hb)  12 g/dL in 8/19 (42%).
There were 4 partial responses, but all have since progressed with
a median response duration of 609 days (range, 107-926). All
responders had chronic GVHD and were on immunosuppression
when progressive disease (PD) occurred. In 3 of 4 responders, PD
occurred at a site of prior response. Among all pts, DLI and/or
interferon were given to 3 pts for PD without response. Six pts died
early (ED) before day 120. Transplant related mortality was 4/6
among those with ED and 5/18 (28%) overall. Among those
without ED or response, 7/9 died from PD. All responders are
alive at a median of 1035 days (range 900-1405). The combination
of anemia and decreased PS was associated with adverse transplant
outcome (P  .035) and reduced survival (P  .004). Responders
had prolonged survival (P  .002) compared to non-responders. In
conclusion, NST for RCC as performed here leads to long term
but not durable partial responses and is associated with prolonged
survival in a minority of pts. Risk stratiﬁcation with simple clinical
factors such as anemia and PS  0 may reduce acute mortality and
enrich the population for potential responders, but further im-
provements in adoptive immunotherapy are necessary before NST
can be more generally applied for RCC.
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ALLOGENEIC TRANSPLANTATION FOR MANTLE CELL LYMPHOMA
Bence-Bruckler, I.A.1, Bierman, P.J.5, Bociek, G.R.5, Stewart, D.A.3,
Gingrich, R.2, Vose, J.M.5, Bredeson, C.N.4, Rosenblum, M.4, Lynch,
J.C.5, Armitage, J.O.5 1. University of Ottawa, Ottawa, ON, Canada;
2. University of Iowa, Iowa City, IA; 3. University of Calgary, Calgary,
AB, Canada; 4. Medical College of Wisconsin, Milwaukee, WI; 5.
University of Nebraska Medical Center, Omaha, NE
The prognosis of mantle cell lymphoma (MCL) is poor with a
median survival of generally less than three years. In an attempt to
improve on the outcome of this disease, high dose therapy in the
form of both autologous and allogeneic stem cell transplantation
(SCT) has been explored. However, recurrences following autol-
ogous transplantation are common. Allogeneic SCT offers the
potential beneﬁts of an uncontaminated stem cells and a graft
versus lymphoma effect.
Thirty-seven patients with MCL underwent allogeneic SCT at
ﬁve institutions between 1994 and 2003. The median age at trans-
plant was 48 (range 34-59) years; 6 patients were female and 31
male. The median interval from diagnosis to transplant was 11
months (range 4-144 months). Seventy percent of patients had
received at least two prior chemotherapeutic regimens and 9% had
failed an autologous SCT. Donor source was matched related
donor (MRD) in 33 (89%) and matched unrelated donor (MUD)
in 4 (11%). Conditioning regimens varied by center; overall 26
patients (70%) received TBI-based conditioning. Donor source
was bone marrow in 14 (38%) and peripheral blood in 23 (62%).
Fourteen grafts (38%) were T-cell depleted and of these, 7 re-
ceived T-cell add-back. With a median follow-up for surviving
patients of 42 months (range 4-98 months), sixteen patients remain
alive post SCT. The cumulative incidence of non-relapse mortality
is 32% at day 100 and 41% at one year post transplant, with the
vast majority of deaths occurring by one year post transplant.
Thirty four of 37 patients were evaluable for acute graft-versus-
host disease (GVHD). The cumulative incidence of acute GVHD
was 62% at 100 days. Of 20 patients evaluable for extensive chronic
GVHD, the cumulative incidence was 30% at one year. Three year
estimates of event-free and overall survival are 39% (95% CI
23%-55%) and 45% (95% CI 28%-61%) respectively. Progressive
disease has been documented in six patients. This data demon-
strates that allogeneic SCT in MCL can result in prolonged disease
control in selected, pretreated patients, although nonrelapse mor-
tality remains a signiﬁcant problem with this approach.
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DISSECTION OF AN MHC MISMATCHED ALLOGENEIC TRANSPLANT
MODEL DURING DONOR CD4CD25 T-CELL FACILITATION OF HE-
MATOPOIETIC PROGENITORS
Hanash, A.M., Levy, R.B. University of Miami School of Medicine,
Miami, FL
Identifying cell populations capable of supporting allogeneic he-
matopoietic stem/progenitor cell engraftment without inducing
GVHD could lead to more potential hematopoietic cell transplant
(HCT) recipients and broaden the acceptable donor pool. We have
examined the effect of CD4CD25 regulatory (T-reg) cells on
engraftment in a sublethal (7.0 Gy TBI) MHC mismatched model
by transplanting donor C57BL/6 (B6) T-regs and T-cell depleted
bone marrow (BM-TCD) into BALB/c recipients and observed
long-term chimerism (p  .05) and diminished rejection (p  .05).
This non-GVHD inducing T-cell population was also associated
with signiﬁcantly greater splenic lineage committed (GM, p 
.001) and multi-potential (HPP, p  .05) donor progenitor colo-
nies 7 days post-BMT. To dissect the allogeneic transplant com-
ponents involved in this progenitor support, splenic day 7 donor
GM progenitors were assessed following transplants eliminating
donor T-regs’ allo-recognition in the recipient and transplants
selectively neutralizing populations in the recipient capable of
allogeneic rejection. T-regs from BALB/c  B6 F1 mice signiﬁ-
cantly increased donor B6 colonies whether transplanted into re-
cipients lacking (BALB/c, H-2d, p  .001) or possessing (BALB.K,
H-2k, p  .05) MHC that was allogeneic to the donor T-regs.
Importantly, when eliminating the recipients’ T-cell resistance by
Table. Inﬂuence of Patient Factors on NST for RCC
Factor
Partial
Response
(%)
Other
(%)
Early
Death
(%)
Across
Groups P
value
Survival P
value
N  4 N  9 N  6 N  19 N  18
Pretreatment
PD at transplant 2 (50) 5 (83) 5 (56) 0.57 .37
Hb < 12 g/dL 1 (25) 3 (33) 4 (67) .48 .06
PS > 0 0 2 (22) 4 (67) .06 <.01
Hb < 12 g/dL and/or
PS > 0 1 (25) 4 (44) 6 (100) .04 <.01
GVHD
aGVHD > 1 0 1 (11) 2/5 (40) .23 .03
cGVHD, ext 4 (100) 3 (33) n/a .76
Nineteen transplants performed with 18 patients. “Other” includes patients who did not
respond or suffer early death. Across group comparison uses a two-tailed Fisher’s
exact test for a 3  2 table. Survival analysis is for 18 patients. P value derived from
univariate log-rank test for each variable.
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transplanting B6 BM-TCD into BALB/c Rag1/ or into BALB/
c B6 F1 recipients, co-transplanting B6 T-regs again augmented
donor colonies (Rag1/, p  .001; F1, p  .01). Notably, co-
transplantation of B6 T-regs increased the already elevated pro-
genitor colony numbers detected in the absence of NK resistance
following transplant of BALB/c  B6 F1 BM-TCD into BALB/c
recipients (p  .001). Finally, when allogeneic antigen, T-cell
resistance, and NK resistance were simultaneously eliminated by
transplanting BALB/c BM-TCD and T-regs into BALB/c recipi-
ents, signiﬁcantly greater progenitor colonies were again observed
(p  .01). In summary, donor CD4CD25 T-cells, which are
capable of supporting long-term allogeneic hematopoietic engraft-
ment without inducing GVHD, are able to support splenic day 7
donor progenitors independent of activation by allogeneic antigen
in the recipient and suppression of host resistance. Furthermore,
the independence from T-cell suppression suggests a novel bio-
logical function of this suppressive population. CD4CD25 T-
cells may thus be useful clinically in supporting engraftment fol-
lowing HCT.
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EFFECT OF VERY HIGH CD34 CELL DOSE ON THE OUTCOME OF
ALLOGENEIC HLA IDENTICAL RELATED TRANSPLANTS
Mathews, V., Khoury, H., Vij, R., Adkins, D., DiPersio, J.F., Devine,
S.M. Stem Cell Transplant and Leukemia Program, Washington Uni-
versity, St Louis, MO
We analyzed outcome in a group patients who recieved very high
CD34 cell dose (20  106 CD34 cells/kg)(Group A). We com-
pared this, with a group of patients who recieved between 3-10 
106 CD34 cells/kg (Group B). There was no signiﬁcant difference
between the groups in recipient age, gender, disease risk or reciept
of sex mismatched product. The donor characteristics were also
similar between both groups except for CD34 cell doses which was
30.1  10.2 cells/kg in group A and 6.2  2 cells/kg in group B
(p  0.000001). The dose of CD3, CD4, CD8, CD19 and
CD16/56 subset of cells were also signiﬁcantly higher in group A
than in group B. All but 10 patients in group A recieved a similar
conditioning regimen and all but 5 in group A recieved GVHD
prophylaxis with single agent cyclosporine. Eight patients in group
A recieved alternative ablative conditioning regimens and 2 re-
cieved reduced intensity conditioning regimens. Five patients in
group A also recieved methotrexate for GVHD prophylaxis.
The results of the outcome in the two groups are given in the
table below. Median time to neutrophil (9.4  2.8 vs 10.4  3.3)
and platelet (11.5  4 vs 15.7  13.3) recovery were not signiﬁ-
cantly different in the two groups. There was a trend towards
earlier engraftment in group A compared to group B. While the
risk of grade 2-4 GVHD was not signiﬁcantly different between
the two groups, the risk of severe (grade 3/4) acute GVHD and
deaths attributable to GVHD were signiﬁcantly higher in group A
compared to group B. Incidence of chronic EGVHD was similar in
both groups. There was a trend towards a lower relapse rate in
group A, though the progression free survival and overall survival
in both the groups were similar.
In conclusion infusion of very high doses of CD34 cells in the
setting of a matched related allogeneic stem cell transplanataion is
associated with signiﬁcant increase risk of severe acute GVHD.
Infusion of the entire unmanipulated stem cell product when the
cell dose is 20  106 CD34 cells/kg is not recommended. The
optimal dose remains to be deﬁned.
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EVEN COAGULASE NEGATIVE STAPHYLOCOCCUS INFECTIONS FOL-
LOWING REDUCED INTENSITY TRANSPLANTATION ARE ASSOCIATED
WITH INCREASED TRANSPLANT COMPLICATIONS AND POORER OVER-
ALL SURVIVAL
Chan, G.W.1, Relias, V.1, Klein, A.K.1, Sprague, K.A.1, Foss, F.M.1,
Miller, K.B.2 1. Tufts-New England Medical Center, Boston, MA; 2.
Beth Israel Deaconess Medical Center, Boston, MA
Reduced intensity transplantation (RIT) is associated with
lower transplant related mortality (TRM) but the incidence of
infectious complications remains controversial. We analyzed the
incidence of bacteremia during the ﬁrst 100 days post-trans-
plantation in 106 patients with various malignancies who un-
derwent a reduced intensity regimen of extracorporeal photo-
pheresis  2 cycles, pentostatin 8 mg/m2 by continuous
intravenous infusion over 48 hours, and total body irradiation
600cGy, followed by allogeneic bone marrow stem cell infusion
from a 6/6 HLA matched related donor (n  68), 5/6 HLA
matched related donor (n  8), 6/6 HLA matched unrelated
donor (n  29), or 5/6 HLA matched unrelated donor (n  1).
GVHD prophylaxis consisted of continuous infusion cyclo-
sporin A and short course methotrexate. All patients received
ﬂuoroquinolone prophylaxis until neutrophil engraftment. Dur-
ing the ﬁrst 100 days post-transplantation, grade 2-4 acute
GVHD occurred in 19% of patients, and 56 patients (53%) had
positive blood cultures. Median days to positive cultures were 21
(range 7 to 97). Blood cultures were positive for coagulase
negative staphylococcus (CoNS) (n  36: 63%), other gram-
positive cocci (GPC) (n  10: 10%), gram-negative rods (GNR)
(n5: 9%), fungus (n  3: 5%), gram-positive rods (GPR) (n 
2: 4%), or anaerobes (n  1: 1%). Recurrent infections (same
species 30 days later) occurred in 7 patients (7%), and multiple
infections with different organisms occurred in 16 patients
(15%). Three patients died of sepsis. The incidence of bac-
teremia was higher in patients with grade 2-4 acute GVHD
versus grade 0-1 acute GVHD (70% versus 45%: p  0.05), and
in mismatched related or matched unrelated transplants versus
matched related transplants (66% versus 46%: p  0.05). Bac-
teremia was associated with higher day 100 TRM (26% versus
11%: p  0.06) and lower median overall survival (OS) (9
months versus 35 months: p  0.01). CoNS bacteremia had
similar day 100 TRM as other GPC bacteremia like staphylo-
coccus aureus and enterococcus (22% versus 38%: p  0.37) and
similar day 100 TRM as non-GPC bacteremia (22% versus
30%: p  0.61). There was a trend towards lower median OS in
patients with CoNS bacteremia versus other GPC bacteremia (7
months versus 14 months: p  0.18). In patients undergoing
RIT, CoNS bacteremia, like other bacteremia, was associated
with increased TRM and poorer overall survival. Future studies
on RIT will need to address the issue of bacteremia, especially
CoNS bacteremia.
Table.
CD34
GVHD
2-4
GVHD
3/4
Chronic
EGVHD
Death—
GVHD Relapses
Alive
(2 years)
Group A
(n  31) 45% 22.5% 72% 16% 19% 48%
Group B
(n  96) 50% 8.3% 75% 6.25% 32% 43%
P 0.5 0.0028 0.54 0.0096 0.13 0.47
Table. Bacteremia Following Reduced Intensity Transplantation
Bacteremia
No
Bacteremia P value
Day 100 TRM 26% 11% P  0.06
Median OS 9 months 35 months P  0.01
CoNS
Bacteremia
Other GPC
Bacteremia P value
Day 100 TRM 22% 38% P  0.37
Median OS 7 months 14 months P  0.18
Bacteremia is associated with higher transplant-related mortality and lower overall
survival. Coagulase-negative staphylococcal bacteremia has a similar TRM and OS as
other gram-positive cocci bacteremia.
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